ABSTRACT
<p><b>OBJECTIVE</b>To investigate the expression of ErbB-3 binding protein-1 (EBP-1), matrix metalloproteinase 9 (MMP-9) and E-cadherin (E-cad) in adenoid cystic carcinoma and their correlation.</p><p><b>METHODS</b>Immunohistochemistry(PV6000 method) was used to detect EBP-1, MMP-9 and E-cad expression in 66 cases of adenoid cystic carcinoma tissues and matched para-cancerous normal tissues. In this study all cases were successfully followed up.</p><p><b>RESULTS</b>The positive expression rate of EBP-1 in adenoid cystic carcinoma tissues was 85%. EBP-1 expression was significantly correlated to pathological pattern and clinical stage (P < 0.05), but not to gender and age. In addition, there was a negative correlation between EBP-1 and E-cad expression, and positive correlation between EBP-1 and MMP-9.</p><p><b>CONCLUSIONS</b>EBP-1 and its correlation with MMP-9 and E-cad may be used as useful indicators for clinical assessment of tumor biological behavior and prognosis in patients with adenoid cystic carcinoma.</p>
Subject(s)
Female , Humans , Male , Middle Aged , Adaptor Proteins, Signal Transducing , Metabolism , Biomarkers, Tumor , Metabolism , Cadherins , Metabolism , Carcinoma, Adenoid Cystic , Metabolism , Pathology , Follow-Up Studies , Lung Neoplasms , Lymphatic Metastasis , Matrix Metalloproteinase 9 , Metabolism , Neoplasm Invasiveness , Neoplasm Staging , RNA-Binding Proteins , Metabolism , Salivary Gland Neoplasms , Metabolism , PathologyABSTRACT
Due to an increased risk of infection, dental implant in organ transplantation patients has long been considered questionable, particularly when the restoration is complicated. Five-year follow-up data of a 45-year-old liver transplant recipient with long-term immunosuppressive therapy was reported. One year after liver transplantation, 11 Brånemark implants were inserted in the maxilla and mandible, using minimally invasive surgery. Oral clinical parameters included peri-implant bone absorption, probing depth, and implant mobility. The measured fifth-year parameters were within normal ranges indicating a stable osseointegration with moderate vertical bone loss. This case report suggests that immunocompromised patients can be successfully rehabilitated with dental implants through careful examination, suitable antibiotic administration, and minimally invasive dental implant procedure.
Subject(s)
Humans , Male , Middle Aged , Dental Implants , Immunosuppressive Agents , Therapeutic Uses , Liver Transplantation , Allergy and ImmunologyABSTRACT
<p><b>OBJECTIVE</b>To investigate the role of transcription factor special AT-rich binding protein 2 (SATB2) in the osteoblasts differentiation of bone marrow stromal cells (BMSC) in vitro.</p><p><b>METHODS</b>Rats bone marrow stromal cells were isolated by Percoll sedimentation and the cells were placed and allowed to attach for three times. After passages, expression plasmid pBABE-hygro-satb2 was constructed, then transfected into BMSC. BMSCs were inoculated in conditioned medium and osteogenic factors were detected by western blotting and reverse transcription polymerase chain reaction (RT-PCR).</p><p><b>RESULTS</b>The morphological observation of BMSC showed either spindle or polygonal pattern. The cellular phenotypic marker of the third passage was CD29 positive and CD34 negative. The growth curve possessed "S" pattern. The intensity of calfilication in BMSC was higher in SATB2 transfection group (IA value 125974 ± 241) than that in the control groups (IA value 178486 ± 406). Moreover, cell migration rate increased in SATB2 transfection group [width of scratch (0.72 ± 0.01) mm] compared with control group [width of scratch (0.83 ± 0.03) mm]. In addition, the mRNA expression of osteogenic factors runt-related transcription factor 2, Osterix, activating transcription factor 4, integrin-binding sialoprotein were upregulated.</p><p><b>CONCLUSIONS</b>Cells cultured with this method have general biological characteristics and osteogenic differentiation potential in vitro. SATB2 can promote osteoblasts differentiation of BMSC.</p>
Subject(s)
Animals , Male , Rats , Activating Transcription Factor 4 , Metabolism , Bone Marrow Cells , Metabolism , Pathology , Cell Differentiation , Cell Movement , Cells, Cultured , Core Binding Factor Alpha 1 Subunit , Metabolism , Integrin-Binding Sialoprotein , Metabolism , Matrix Attachment Region Binding Proteins , Genetics , Metabolism , Osteoblasts , Cell Biology , Osteogenesis , Plasmids , RNA, Messenger , Metabolism , Rats, Sprague-Dawley , Stromal Cells , Metabolism , Pathology , Thy-1 Antigens , Metabolism , Transcription Factors , Genetics , Metabolism , TransfectionABSTRACT
<p><b>OBJECTIVE</b>To study the p53/p21 fusion gene as a potential fusion gene for the gene therapy of human oral squamous cell carcinoma.</p><p><b>METHODS</b>p21 cDNA was obtained from normal human embryonic lung cells by RT-PCR, fusing with p53 gene. The recombinant plasmid pcDNA-p53/p21 was constructed by inserting the p53/p21 fusion gene into eukaryotic expression vector pcDNA3.1 and subsequently transfected into human oral squamous cell carcinoma cell line (Tca8113) with lipofectamine. RT-PCR and Western blot were used to demonstrate the expression of p53/p21 fusion gene. Using clonal formation experiment and (3)H-TdR incorporation assay were used to evaluate the clonal formation and proliferation ability of Tca8113 cells.</p><p><b>RESULTS</b>It was observed that p53/p21 fusion gene could inhibit clonal formation and proliferation of human oral carcinoma. RT-PCR and Western blot demonstrated that it was the expression of exogenous p53/p21 fusion gene that led to the above results.</p><p><b>CONCLUSIONS</b>Transfection of p53/p21 fusion gene to Tca8113 cells could inhibit the tumor cell proliferation and clone formation in vitro, and make itself a potential fusion gene for the gene therapy of human oral squamous cell carcinoma.</p>